|
Oxford Molecular has sold its software division to Pharmacopeia of the US for £18m, and the remaining business will now be liquidated. 10-Aug-2000 Oxford Molecular is selling Cambridge Discovery Chemistry to Millennium Pharmaceuticals for £35m, in order to reduce debt. 07-Jul-2000 Oxford Molecular, the lossmaking biotechnology group, has received a takeover approach from an unnamed company. 17-Feb-2000 Oxford Molecular is to change the name of its Cambridge Combinatorial business to Cambridge Discovery Chemistry, in order to reflect its focus on the discovery of new chemical entities. 01-Oct-1999 Oxford Molecular is to close six of its nine US offices and restructure its operations into two divisions - software solutions and discovery solutions. 19-Mar-1999 Oxford Molecular is to acquire the remaining stake in Cambridge Combinatorial for £12m. 30-Sep-1998 Oxford Molecular is to invest £2.5m in MicroGenics, a new company set up to develop screening systems for antibiotics. 29-Jun-1998 Oxford Molecular is set to acquire Chemical Design Holdings, the pharmaceutical software company, for about £6m. 06-Apr-1998 Oxford Molecular is acquiring a 20% stake in Cambridge Drug Discovery, the rapid drug screening company, for up to £5m as part of a strategy to become a low-risk provider of drug services. 18-Dec-1997 Oxford Molecular is planning to transform itself from a pharmaceutical software designer into a drug designer, and has taken an option to acquire Cambridge Combinatorial, the new biotechnology company. 05-Aug-1997 Oxford Molecular is acquiring Genetics Computer and MRL Automation, two US software companies that specialise in the development of new drugs, funded by a £30m rights issue. 09-May-1997 Oxford Molecular has won a US patent on software that manages libraries of molecular shapes. 22-Nov-1996 Oxford Molecular is forming an alliance with Prolifix, the biotechnology company, in which Prolifix will fund research into drug development and pay royalty fees to Oxford Molecular for its drug design software. 01-Nov-1996 Oxford Molecular has announced a research deal with Alizyme in which they will develop compounds to treat obesity. 11-Jun-1996 Oxford Molecular, the drug design concern, is to undergo a three-year joint research programme with Yamanouchi Pharmaceutical of Japan. 19-Apr-1996 Oxford Molecular, the developer of software for the drugs industry, has bought three US companies - Chemical Informatics, MacVector and Health Designs. 01-Feb-1996 Oxford Molecular is linking with Perkin-Elmer to jointly develop software for quickly identifying genetic data for use in drug design. 18-Sep-1995
|